Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2022-01-10 00:00:00 ET · period of report 2022-01-06 · accession 0001209191-22-002751 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-10 | 2022-01-06 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | S - Sale+OE | $23.05 | -538 | 1,788 | -23% | -$12.4K |
| D | 2022-01-10 | 2022-01-06 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | M - OptEx | — | +1,286 | 2,326 | +124% | — |
| D | 2022-01-10 | 2022-01-06 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | M - OptEx | $0.00 | -1,286 | 2,573 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-06 | S | D | 538 | $23.05 | 1,788 | D | — | — | |
| 2 | Common | Common Stock | 2022-01-06 | M | A | 1,286 | — | 2,326 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F2) Includes 233 shares of the Issuer's common stock acquired by the reporting person on November 15, 2021 pursuant to an employee stock purchase program. |
| 3 | Derivative | Restricted Stock Units | 2022-01-06 | M | D | 1,286 | $0.00 | 2,573 | D | — · — to — | 1,286 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F4) The restricted stock units vest in four equal annual installments beginning January 6, 2021. |